The Belgian Pharmaceutical Conference: March 17th 2011  - Diamant Conference Centre Brussels

BeAPP and pharma.be present the first Belgian Pharmaceutical Conference.
The growing importance of data on the internet and the societal move to e-healthcare raises questions on transparency, compliance to local regulations, information available to the lay public, the reliability of data and the relationships between stakeholders. What will the impact be on industry and its position in the healthcare community?

The Belgian Pharmaceutical Conference invites industry and healthcare professionals to join the discussion on topics that will shape e-health in the coming years, and to interact with experts, colleagues and service providers offered by the numerous networking opportunities.

The conference will be held on the 17th March from 9 a.m. to 6 p.m. Address: Diamant Building, Reyerslaan 80, 1030 Brussels.

We look forward to welcoming you there.

Click here for the program flyer brochure

More information on http://www.pharmaconference.be/

Register online

Presentations

• Prof.dr. Herman Nys, Director of the Centre for Biomedical Ethics and Law - Patient rights and E-Health Research
• Angelika Joos, Pharma. D - Head Regulatory Policy Merck Sharp & Dohme (Europe) - Transparency and disclosure of clinical trials and results
• Magali Geens - Director Health Research InSites Consulting - New Means of Communication and Information Gathering
• Ingrid Maes - Director Healthcare, Pharma & Life Sciences PwC - Economic footprint of clinical trials in Belgium
• dr. Greet Musch - Director General Pre-Authorisation FAGG/AFMPS - The Belgian EU Presidency and clinical trials
• Prof.dr. Leo Neels, Algemeen directeur pharma.be - The initiative to promote clinical trials in Belgium
• Peter Lloyd, PhD - Head PKPD Novartis Biologicals - Challenges in early clinical drug development of biologicals
• Prof.dr. Peter De Deyn - Scientific Director Institute Born-Bunge University of Antwerp - Ethical concerns in early clinical drug development
• Walter Janssens PhD - Coordinator Early Phase Development FAGG/AFMPS - cGMP in early clinical drug development
• dr. Monique Podoor, President BeAPP - Clinical Trials: Trends in patient recruitment and retention - A new approach in France
• Alexander Roussanov - Associate Hogan Lovells International - KOL Management: The do's and don'ts for compliance - a Pharma case study
• dr. Luc Maes - Program Manager eHealth - The Belgian eHealth Platform
• Carl Vanhaesendonck - Life Sciences Technology Support C3i/Anna Stoyanova - Client Manager C3i - Global Trials Support Challenges - Essential guidelines to increase clinical study effectiveness
• An Vijverman - Lawyer (partner) Dewallens & partners - Specialised in Health Law - Privacy laws for data exchange in the healthcare sector

BELGIAN ASSOCIATION OF PHARMACEUTICAL PHYSICIANS

The Belgian Association of Pharmaceutical Physicians (BeAPP) is a non-profit organisation founded in 1972 by physicians employed in the Pharmaceutical Industry in Belgium. Its bylaws were published in the Belgian Official Journal of 21 November 1974. Since then, BeAPP has made efforts to increase the awareness and recognition of the important role of physicians within the pharmaceutical industry. Pharmaceutical Medicine is the medical and scientific discipline concerned with the discovery, development, evaluation, registration and monitoring of medicines for human use, as well as with the medical aspects of their commercialisation and this for the benefit of patients and the public health at large. BeAPP has endeavoured to portray the image of this profession, as favourably as possible, not just towards other physicians but also towards regulatory and academic institutions. www.beapp.be

President of BeAPP, Dr. Monique Podoor, mpodoor@pharmakon.lu

PHARMA.BE

As a partner to doctors, pharmacists, authorities and other stakeholders, pharma.be ensures the promotion of the best available healthcare treatment in the field of medicines through therapeutic innovation. The priority of pharmaceutical laboratories and doctors is to offer patients access to the best suited medicine, according to his or her personal characteristics. This means creating a budget for innovation. pharma.be and the pharmaceutical laboratories favour a policy which, through branded medicines, permits the funding of research and development costs for the medicines of the future, thanks to a budget which matches real healthcare needs. pharma.be, the Belgian Pharmaceutical Industry Association, combines 150 pharmaceutical companies based in Belgium.www.pharma.be

Director General pharma.be, Prof. dr. Leo Neels, ln@pharma.be www.pharma.be